This site uses cookies to collect activity data and personalize content. By continuing to navigate this site, you agree to allow us to collect information using cookies. Learn more about how we care for your data in our privacy notice.

Accept

Stakeholder preferences for a new rotavirus vaccine candidate

Current live, oral rotavirus vaccines (LORVs) are reducing severe diarrhea in all settings, but they are not as effective in places with the highest burden. Alternative approaches in advanced clinical development include injectable next-generation rotavirus vaccines (iNGRVs), which have the potential to better protect children against disease, be combined with existing routine immunizations, and be even more affordable than the current LORVs. PATH conducted a series of studies to understand the real public health value of iNGRVs to help inform decisions by international agencies, funders, vaccine manufacturers, and countries. This included a feasibility and acceptability study with national stakeholders and healthcare providers in Ghana, Kenya, Malawi, Peru, Senegal, and Sri Lanka to assess their preferences for different hypothetical rotavirus vaccine options. These briefs provide an overview of the results in each of the study countries.

Publication date: October 2021

Available materials

    1. Ghana stakeholder preferences for a new rotavirus vaccine candidate 443.7 KB PDF
    2. Kenya stakeholder preferences for a new rotavirus vaccine candidate 451.6 KB PDF
    3. Malawi stakeholder preferences for a new rotavirus vaccine candidate 446.2 KB PDF
    4. Peru stakeholder preferences for a new rotavirus vaccine candidate 451.3 KB PDF
    5. Senegal stakeholder preferences for a new rotavirus vaccine candidate 478.6 KB PDF
    6. Sri Lanka stakeholder preferences for a new rotavirus vaccine candidate 350.5 KB PDF